Free Trial
NASDAQ:EVAX

Evaxion A/S Q3 2023 Earnings Report

Evaxion A/S logo
$2.83 -0.10 (-3.41%)
Closing price 08/8/2025 03:52 PM Eastern
Extended Trading
$2.82 0.00 (-0.18%)
As of 08/8/2025 06:21 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Evaxion A/S EPS Results

Actual EPS
-$10.50
Consensus EPS
-$9.50
Beat/Miss
Missed by -$1.00
One Year Ago EPS
N/A

Evaxion A/S Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Evaxion A/S Announcement Details

Quarter
Q3 2023
Time
Q3 2023 Earnings Release
Conference Call Date
Tuesday, December 19, 2023
Conference Call Time
2:00AM ET

Upcoming Earnings

Evaxion A/S' Q2 2025 earnings is scheduled for Wednesday, August 13, 2025, with a conference call scheduled at 8:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

Evaxion A/S Earnings Headlines

Why AMZN, GOOG, MSFT might destroy NVDA
Investing Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla and Nvidia are all on the verge of major disruption. To help protect anyone with money invested in them, he's sharing three exciting stocks to replace them with. He gives away the names and tickers completely free in his brand-new "Sell This, Buy That" broadcast.
Evaxion CEO Departs; CFO and Interim CEO Appointed
See More Evaxion A/S Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Evaxion A/S? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Evaxion A/S and other key companies, straight to your email.

About Evaxion A/S

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers. Its programs also include some vaccines that are in pre-clinical stage, which includes EVX-B1 for the prevention of S. aureus-induced skin and soft tissue infections in patients undergoing elective abdominal hernia surgery; EVX-B2 to target diseases caused by N. gonorrhoeae; EVX-B3 for eliciting strong humoral antibody and cellular immune response to the bacterial pathogen; and EVX-V1, viral vaccine product candidate for targeting Cytomegalovirus. Evaxion Biotech A/S was incorporated in 2008 and is based in Horsholm, Denmark.

View Evaxion A/S Profile

More Earnings Resources from MarketBeat